Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1.

导出 LinkOut

翻译打印收藏纠错

作者： Jize,Liu ^[1] ; Xiaomin,Ma ^[2] ; Chuxuan,Liu ^[1] ; Yang,Cheng ^[3] ; Bingjun,Li ^[3] ; Wenjie,Zhang ^[1] ; Runzhi,Zeng ^[2] ; Qishuai,Chen ^[3] ; Yun,Zhang ^[3] ; Sanyuan,Hu ^[1]

作者单位： Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China. ^[1] Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. ^[2] Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ^[3]

关键词 CD8+ TCELL anti-PD1 antibodies colorectal cancer immunotherapy macrophages mesenchymal stem cells tumor microenvironment

DOI 10.3389/fphar.2023.1136614

PMID 36843945

发布时间 2023-02-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2023年14卷

1136614页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除